-
Je něco špatně v tomto záznamu ?
Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study
T. Resál, P. Bacsur, C. Keresztes, A. Bálint, R. Bor, A. Fábián, B. Farkas, K. Katsanos, G. Michalopoylos, DG. Ribaldone, M. Attauabi, M. Zhao, HA. Barak, H. Yanai, C. Bezzio, A. Rispo, F. Castiglione, A. Bar-Gil Shitrit, D. Pugliese, A. Armuzzi,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
Grantová podpora
K22-143549
Hungarian Scientific Research
125377
National Research, Development and Innovation Office
UNKP-22-3-SZTE-278
New National Excellence Program of the Ministry of Human Capacities
BO/00598/19/5
Janos Bolyai Research
Géza Hetényi Research
Albert Szent-Györgyi Medical School, University of Szeged
PubMed
37542737
DOI
10.1093/ibd/izad135
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- indukce remise MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- kolektomie MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- piperidiny * terapeutické užití MeSH
- pyrimidiny * terapeutické užití MeSH
- retrospektivní studie MeSH
- stupeň závažnosti nemoci MeSH
- ulcerózní kolitida * farmakoterapie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
BACKGROUND AND AIMS: Tofacitinib (TFB) appears to be effective in the treatment of ulcerative colitis (UC); however, available real-world studies are limited by cohort size. TFB could be an option in the treatment of acute severe ulcerative colitis (ASUC). We aimed to investigate efficacy and safety of TFB in moderate-to-severe colitis and ASUC. METHODS: This retrospective, international cohort study enrolling UC patients with ≥6-week follow-up period was conducted from February 1 to July 31, 2022. Indications were categorized as ASUC and chronic activity (CA). Baseline demographic and clinical data were obtained. Steroid-free remission (SFR), colectomy, and safety data were analyzed. RESULTS: A total of 391 UC patients (median age 38 [interquartile range, 28-47] years; follow-up period 26 [interquartile range, 14-52] weeks) were included. A total of 27.1% received TFB in ASUC. SFR rates were 23.7% (ASUC: 26.0%, CA: 22.8%) at week 12 and 41.1% (ASUC: 34.2%, CA: 43.5%) at week 52. The baseline partial Mayo score (odds ratio [OR], 0.850; P = .006) was negatively associated with week 12 SFR, while biologic-naïve patients (OR, 2.078; P = .04) more likely achieved week 52 SFR. The colectomy rate at week 52 was higher in ASUC group (17.6% vs 5.7%; P < .001) and decreased with age (OR, 0.94; P = .013). A total of 67 adverse events were reported, and 17.9% resulted in cessation of TFB. One case of thromboembolic event was reported. CONCLUSIONS: TFB is effective in both studied indications. TFB treatment resulted in high rates of SFR in the short and long terms. Higher baseline disease activity and previous biological therapies decreased efficacy. No new adverse event signals were found.
4th Medical Department Charles University Prague Prague Czech Republic
Centre International de Recherche et Infectologie INSERM U1111 Lyon France
Department of Biomedical Sciences Humanitas University Pieve Emanuele Italy
Department of Gastroenterology and Hepatology University Hospital Centre Zagreb Zagreb Croatia
Department of Gastroenterology Lyon Sud Hospital Hospices Civils de Lyon Lyon France
Department of Gastroenterology Military Hospital Medical Centre State Health Centre Budapest Hungary
Department of Gastroenterology Pennine Acute Hospitals NHS Trust Manchester United Kingdom
Department of Gastroenterology University Medical Centre Ljubljana Ljubljana Slovenia
Department of Internal Medicine and Oncology Semmelweis University Budapest Hungary
Department of Medical Sciences University of Turin Turin Italy
Department of Nutrition School of Medicine University of Zagreb Zagreb Croatia
Department of Surgery Oncology and Gastroenterology University of Padua Padua Italy
Division of Gastroenterology McGill University Health Centre Montreal Quebec Canada
Division of Gastroenterology Rabin Medical Center Petah Tikva Israel
Gastroenterology Department General Hospital of Athens G Gennimatas Athens Greece
Gastroenterology Unit Azienda Ospedale Università di Padova Padua Italy
Gastrounit Copenhagen University Hospital Amager and Hvidovre Hvidovre Denmark
IBD Center IRCCS Humanitas Research Hospital Rozzano Italy
IBD Unit Gastroenterology Unit Rho Hospital ASST Rhodense Rho Italy
Institute for Translational Medicine Medical School University of Pécs Pécs Hungary
Irkutsk Scientific Center of Surgery and Traumatology Irkutsk Russia
Moscow Clinical Scientific Center named after A S Loginov Moscow Russia
National Medical Research Center of Coloproctology named after A N Ryzhykh Moscow Russia
Research Institute of Health Organization and Medical Management Moscow Russia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24014017
- 003
- CZ-PrNML
- 005
- 20240905133416.0
- 007
- ta
- 008
- 240725s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/ibd/izad135 $2 doi
- 035 __
- $a (PubMed)37542737
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Resál, Tamás $u Division of Gastroenterology, Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary
- 245 10
- $a Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study / $c T. Resál, P. Bacsur, C. Keresztes, A. Bálint, R. Bor, A. Fábián, B. Farkas, K. Katsanos, G. Michalopoylos, DG. Ribaldone, M. Attauabi, M. Zhao, HA. Barak, H. Yanai, C. Bezzio, A. Rispo, F. Castiglione, A. Bar-Gil Shitrit, D. Pugliese, A. Armuzzi, EV. Savarino, M. Kolar, M. Lukáš, E. Chashkova, R. Filip, A. Rozieres, S. Nancey, Ž. Krznarić, E. Schäfer, T. Szamosi, P. Sarlós, M. Franko, D. Drobne, OV. Knyazev, AV. Kagramanova, J. Limdi, P. Wetwittayakhlang, PL. Lakatos, N. Maharshak, L. Bannon, T. Nyári, Z. Szepes, K. Farkas, TFB Study Group , T. Molnár
- 520 9_
- $a BACKGROUND AND AIMS: Tofacitinib (TFB) appears to be effective in the treatment of ulcerative colitis (UC); however, available real-world studies are limited by cohort size. TFB could be an option in the treatment of acute severe ulcerative colitis (ASUC). We aimed to investigate efficacy and safety of TFB in moderate-to-severe colitis and ASUC. METHODS: This retrospective, international cohort study enrolling UC patients with ≥6-week follow-up period was conducted from February 1 to July 31, 2022. Indications were categorized as ASUC and chronic activity (CA). Baseline demographic and clinical data were obtained. Steroid-free remission (SFR), colectomy, and safety data were analyzed. RESULTS: A total of 391 UC patients (median age 38 [interquartile range, 28-47] years; follow-up period 26 [interquartile range, 14-52] weeks) were included. A total of 27.1% received TFB in ASUC. SFR rates were 23.7% (ASUC: 26.0%, CA: 22.8%) at week 12 and 41.1% (ASUC: 34.2%, CA: 43.5%) at week 52. The baseline partial Mayo score (odds ratio [OR], 0.850; P = .006) was negatively associated with week 12 SFR, while biologic-naïve patients (OR, 2.078; P = .04) more likely achieved week 52 SFR. The colectomy rate at week 52 was higher in ASUC group (17.6% vs 5.7%; P < .001) and decreased with age (OR, 0.94; P = .013). A total of 67 adverse events were reported, and 17.9% resulted in cessation of TFB. One case of thromboembolic event was reported. CONCLUSIONS: TFB is effective in both studied indications. TFB treatment resulted in high rates of SFR in the short and long terms. Higher baseline disease activity and previous biological therapies decreased efficacy. No new adverse event signals were found.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a ulcerózní kolitida $x farmakoterapie $7 D003093
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a pyrimidiny $x terapeutické užití $7 D011743
- 650 12
- $a piperidiny $x terapeutické užití $7 D010880
- 650 _2
- $a kolektomie $7 D003082
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Bacsur, Péter $u Division of Gastroenterology, Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary
- 700 1_
- $a Keresztes, Csilla $u Department for Medical Communication and Translation Studies, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary
- 700 1_
- $a Bálint, Anita $u Division of Gastroenterology, Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary
- 700 1_
- $a Bor, Renáta $u Division of Gastroenterology, Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary
- 700 1_
- $a Fábián, Anna $u Division of Gastroenterology, Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary
- 700 1_
- $a Farkas, Bernadett $u Division of Gastroenterology, Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary
- 700 1_
- $a Katsanos, Kostas $u Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
- 700 1_
- $a Michalopoylos, George $u Gastroenterology Department, General Hospital of Athens G. Gennimatas, Athens, Greece
- 700 1_
- $a Ribaldone, Davide Giuseppe $u Department of Medical Sciences, University of Turin, Turin, Italy
- 700 1_
- $a Attauabi, Mohamed $u Department of Gastroenterology and Hepatology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark
- 700 1_
- $a Zhao, Mirabella $u Gastrounit, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark $1 https://orcid.org/0000000283924860
- 700 1_
- $a Barak, Hadar Amir $u Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel
- 700 1_
- $a Yanai, Henit $u Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel
- 700 1_
- $a Bezzio, Cristina $u IBD Unit/Gastroenterology Unit, Rho Hospital, ASST Rhodense, Rho, Italy $1 https://orcid.org/0000000300768549
- 700 1_
- $a Rispo, Antonio $u IBD Unit Department, Clinical Medicine and Surgery, Azienda Ospedaliera Universitaria Federico II of Naples, Naples, Italy
- 700 1_
- $a Castiglione, Fabiana $u IBD Unit Department, Clinical Medicine and Surgery, Azienda Ospedaliera Universitaria Federico II of Naples, Naples, Italy
- 700 1_
- $a Bar-Gil Shitrit, Ariella $u Digestive Diseases Institute, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel
- 700 1_
- $a Pugliese, Daniela $u IBD Center, Centro Malattie Apparato Digerente, Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- 700 1_
- $a Armuzzi, Alessandro $u IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Italy $u Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy $1 https://orcid.org/0000000315720118
- 700 1_
- $a Savarino, Edoardo Vincenzo $u Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy $u Gastroenterology Unit, Azienda Ospedale Università di Padova, Padua, Italy
- 700 1_
- $a Kolar, Martin $u IVth Medical Department, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Lukáš, Milan $u IVth Medical Department, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Chashkova, Elena $u Irkutsk Scientific Center of Surgery and Traumatology, Irkutsk, Russia
- 700 1_
- $a Filip, Rafał $u Department of Gastroenterology with IBD, Unit of Clinical Hospital No. 2 im. Sw. Jadwigi Królowej, Rzeszow, Poland
- 700 1_
- $a Rozieres, Aurore $u Department of Gastroenterology, Lyon-Sud Hospital, Hospices Civils de Lyon, Lyon, France $u Centre International de Recherche et Infectologie, INSERM U1111, Lyon, France
- 700 1_
- $a Nancey, Stéphane $u Department of Gastroenterology, Lyon-Sud Hospital, Hospices Civils de Lyon, Lyon, France $u Centre International de Recherche et Infectologie, INSERM U1111, Lyon, France
- 700 1_
- $a Krznarić, Željko $u Department of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Zagreb, Croatia $u Department of Nutrition, School of Medicine, University of Zagreb, Zagreb, Croatia
- 700 1_
- $a Schäfer, Eszter $u Department of Gastroenterology, Military Hospital Medical Centre, State Health Centre, Budapest, Hungary
- 700 1_
- $a Szamosi, Tamás $u Department of Gastroenterology, Military Hospital Medical Centre, State Health Centre, Budapest, Hungary
- 700 1_
- $a Sarlós, Patrícia $u Division of Gastroenterology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary $u Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary
- 700 1_
- $a Franko, Matej $u Department of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Drobne, David $u Department of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia $u Department of Gastroenterology, University Medical Centre Ljubljana, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia $1 https://orcid.org/000000032734675X
- 700 1_
- $a Knyazev, Oleg V $u Moscow Clinical Scientific Center named after A. S. Loginov, Moscow, Russia $u National Medical Research Center of Coloproctology named after A. N. Ryzhykh, Moscow, Russia
- 700 1_
- $a Kagramanova, Anna V $u Moscow Clinical Scientific Center named after A. S. Loginov, Moscow, Russia $u Research Institute of Health Organization and Medical Management, Moscow, Russia
- 700 1_
- $a Limdi, Jimmy $u Department of Gastroenterology, Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom
- 700 1_
- $a Wetwittayakhlang, Panu $u Division of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada $u Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand $1 https://orcid.org/0000000259624112
- 700 1_
- $a Lakatos, Peter L $u Division of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada $u Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Maharshak, Nitsan $u Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- 700 1_
- $a Bannon, Lian $u Department of Gastroenterology and Hepatology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark
- 700 1_
- $a Nyári, Tibor $u Department of Medical Physics and Informatics, Albert Szent-Györgyi Medical School University of Szeged, Szeged, Hungary
- 700 1_
- $a Szepes, Zoltán $u Division of Gastroenterology, Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary
- 700 1_
- $a Farkas, Klaudia $u Division of Gastroenterology, Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary
- 700 1_
- $a Molnár, Tamás $u Division of Gastroenterology, Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary $1 https://orcid.org/0000000249137599
- 710 2_
- $a TFB Study Group
- 773 0_
- $w MED00002243 $t Inflammatory bowel diseases $x 1536-4844 $g Roč. 30, č. 5 (2024), s. 768-779
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37542737 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133410 $b ABA008
- 999 __
- $a ok $b bmc $g 2143671 $s 1225883
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 30 $c 5 $d 768-779 $e 20240502 $i 1536-4844 $m Inflammatory bowel diseases $n Inflamm Bowel Dis $x MED00002243
- GRA __
- $a K22-143549 $p Hungarian Scientific Research
- GRA __
- $a 125377 $p National Research, Development and Innovation Office
- GRA __
- $a UNKP-22-3-SZTE-278 $p New National Excellence Program of the Ministry of Human Capacities
- GRA __
- $a BO/00598/19/5 $p Janos Bolyai Research
- GRA __
- $p Géza Hetényi Research
- GRA __
- $p Albert Szent-Györgyi Medical School, University of Szeged
- LZP __
- $a Pubmed-20240725
